Novel platelet activation receptor CLEC-2: from discovery to prospects.
about
Galactose 6-O-sulfotransferases are not required for the generation of Siglec-F ligands in leukocytes or lung tissuePodoplanin: emerging functions in development, the immune system, and cancerTyrosine kinase inhibitors for the treatment of rheumatoid arthritisNeutrophil cell surface receptors and their intracellular signal transduction pathways.The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture.CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development.Bidirectional crosstalk between platelets and monocytes initiated by Toll-like receptor: an important step in the early defense against fungal infections?Crosstalk between Platelets and the Immune System: Old Systems with New DiscoveriesVascular tumours in infants. Part II: vascular tumours of intermediate malignancy [corrected] and malignant tumours.Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation.Platelets and cancer: a casual or causal relationship: revisited.CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo.SLAP/SLAP2 prevent excessive platelet (hem)ITAM signaling in thrombosis and ischemic stroke in mice.C-type lectin like receptor 2 (CLEC-2) signals independently of lipid raft microdomains in platelets.PDGF upregulates CLEC-2 to induce T regulatory cellsIdentification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasisCHD4-regulated plasmin activation impacts lymphovenous hemostasis and hepatic vascular integrity.A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis.Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.The snake venom rhodocytin from Calloselasma rhodostoma- a clinically important toxin and a useful experimental tool for studies of C-type lectin-like receptor 2 (CLEC-2)Cancer-associated pathways and biomarkers of venous thrombosis.Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood.Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice.Platelet "first responders" in wound response, cancer, and metastasis.CLEC-2 is required for development and maintenance of lymph nodes.CLEC-2 and podoplanin, partners again.Podoplanin-expressing inflammatory macrophages activate murine platelets via CLEC-2.Why do we study animal toxins?Platelet CLEC-2: a molecule with 2 faces.C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets.Functional expression of the Fc-fused extracellular domains of group II membrane proteins.ASK1 facilitates tumor metastasis through phosphorylation of an ADP receptor P2Y12 in platelets.Role of platelets and platelet receptors in cancer metastasisThrombus Formation and Propagation in the Onset of Cardiovascular Events
P2860
Q24622257-AB0711BC-8E82-4408-9BEA-2CC8657713BCQ28275310-5E005FFE-4A0D-44C9-AD5E-184F5302D574Q28674280-200B1D41-E459-4B8F-938A-65398E5B1BEDQ30009577-871858B5-1D5C-4DFC-A425-4245A3B4B9B7Q30090178-658AE4FA-1E14-40D5-8DDA-90F9085BB548Q30514065-282D08DE-151D-4106-AE0D-C3434003BC73Q33401507-681EBCAC-83A7-4CE3-801B-3A4E8C0258F6Q33403517-DB013B97-4BD3-48A0-84DF-AA197EA8303DQ33416117-996A8F4C-3582-4E6C-94C1-FF8FA5B0283CQ33416935-85937D04-007C-49D6-92A0-701F33E59AB5Q34294719-BA7EC8F0-5073-42DF-991F-1F1EF0DE0D23Q34318501-B3C68E03-EF76-487F-9BE1-400F225F8761Q34802412-C8079D36-8262-42CD-BB0B-9B3BEB8F747BQ34902163-7C0B88C2-573E-49C4-8735-41668BB7F7FDQ36557110-D254A1CE-C931-434C-ABC2-A4895FDA5A30Q36618989-2845AB10-D9A5-4DAE-BEB9-DA75EE0BDFA3Q36951765-94913E83-B1E3-4589-965A-DE8888DA0E7CQ37631100-11C91C84-90D2-457B-8EAB-236CB199ABBBQ37725087-0A9A726D-8CA2-4015-92D4-4619DAC3A28CQ38099700-569CC7B1-9FD8-4DEF-B69F-9A51083D0339Q38642557-4BE9DADD-C9F1-4806-9FB2-91CF08F1BAD6Q38783449-71B7B65F-15CE-4611-824A-77DC5B30F539Q39028469-0C0D41C1-23E0-4D25-9A42-EDAC9FB476DCQ39060831-C0BA5649-7DAE-4C44-9878-EE76755D3D6FQ39449769-45C7E59A-A0F4-43FD-BA7B-D68D65ADF1AFQ39675353-3206DAE8-1AB7-40CF-A287-17F384E7A3D1Q39773886-FAE8A640-15D8-4FFA-97F7-9DCEBE94AF56Q42143962-73A7DF47-C021-48E9-B5C4-E4EB6AC3EA4AQ42957096-3FA21525-8E04-4198-8B23-DC5BD5E9274EQ46004241-E5B28615-D6D0-48AF-BCEB-9D86A49BB61FQ50351148-37E13FA3-8FEF-4DB4-A30D-B556492F3188Q51745447-E104ADA1-B19B-42BD-A922-F07E5A87DB33Q52760854-E9407EFA-D8A0-4AFB-962F-290DE24BC3C6Q57280930-A2EC2070-C70C-4CA3-BFDA-F234B490CA54Q58805706-52939471-A4E5-4894-B04C-936D08D05400
P2860
Novel platelet activation receptor CLEC-2: from discovery to prospects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel platelet activation receptor CLEC-2: from discovery to prospects.
@en
Novel platelet activation receptor CLEC-2: from discovery to prospects.
@nl
type
label
Novel platelet activation receptor CLEC-2: from discovery to prospects.
@en
Novel platelet activation receptor CLEC-2: from discovery to prospects.
@nl
prefLabel
Novel platelet activation receptor CLEC-2: from discovery to prospects.
@en
Novel platelet activation receptor CLEC-2: from discovery to prospects.
@nl
P2093
P2860
P1476
Novel platelet activation receptor CLEC-2: from discovery to prospects.
@en
P2093
P2860
P356
10.1111/J.1538-7836.2011.04335.X
P478
P577
2011-07-01T00:00:00Z